bioRxivNeurosciencePreprint
Adeno-associated virus (AAV) reduces cortical dendritic complexity in a TLR9-dependent manner
Christos Michael SurianoiD, Jessica L. VerpeutiD, Neerav KumariD, Jie MaiD, Caroline JungiD, Lisa M. BoulangeriD
Abstract
Recombinant adeno-associated viruses (AAVs) allow rapid and efficient gene delivery in the nervous system. AAVs are widely used in research and are the basis of multiple FDA-approved gene therapies. Here, we find that the immune response to AAVs genome reduces dendritic complexity in mammalian cortex. Dendritic loss associated with AAV-mediated gene delivery occurs at experimentally-relevant titers, cannot be explained by responses to transgene expression or surgery, and is not restricted to a particular capsid serotype, encoded transgene, promoter, or production facility. AAV-associated dendritic loss is accompanied by a decrease in the frequency and amplitude of miniature excitatory postsynaptic currents (mEPSCs) and upregulation of immune molecules that can limit dendritic complexity and synaptic transmission. Blocking detection of unmethylated CpG-rich DNA via Toll-like receptor 9 (TLR9) protects dendritic complexity, suggesting that immunodetection of a core feature of the AAV genome triggers dendritic loss. These results reveal previously unsuspected impacts of AAV on neuronal structure and function and identify TLR9 inhibitors as important tools to improve the safety and efficacy of AAV-mediated gene delivery in the nervous system.
- organism: mouse
- assay: electronic health records
- research focus: drug response / drug discovery
- approach: experimental assay
- Citations
- 17
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Adeno-Associated Virus-Induced Neurotoxicity is Prevented by CpG Depletion
Connor E. Dunn, Brigett V. Carvajal, … Lisa M. Boulanger·Molecular Therapy AdvancesPeer-reviewed·Feb 19, 2026
- Antibodies against the capsid induced after intracranial AAV administration limits second administration in a dose dependent manner
Y.-G. Xu, Xiaoni Bai, … Wen Li·Molecular Therapy — Methods & Clinical DevelopmentPeer-reviewed·Jan 25, 2025
- AAV-DJ is Superior to AAV9 for Targeting Brain and Spinal Cord, and De-Targeting Liver Across Multiple Delivery Routes in Mice
Monika Chauhan, Audrey L. Daugherty, … Christina A. Pacak·Journal of Translational MedicinePeer-reviewed·Sep 5, 2024
- Adeno-associated viruses (AAVs) induce dose-dependent neonatal ventriculomegaly following intracerebroventricular administration
Luke L. Liu, Ania Noguera, … Ryann M. Fame·bioRxiv·Dec 31, 2025
- Mechanisms of AAV neutralization by human alpha-defensins
Jessica M. Porter, Kaitlin R. Hulce, … Jason G. Smith·PLoS PathogensPeer-reviewed·Jul 18, 2025
- Optical opening of the blood brain barrier for targeted and ultra-sparse viral infection of cells in the mouse cortex
Patrick L. Reeson, Roobina Boghozian, … Craig E. Brown·Cell Reports MethodsPeer-reviewed·Jun 1, 2023